The evolution of prostate cancer therapy: Targeting the androgen receptor (AR)

Frontiers in Oncology

Volumn 4, Issue OCT, 2014, Pages

  Aragon Ching, Jeanny B ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; DOCETAXEL; ENZALUTAMIDE; GALETERONE; GLUCOCORTICOID; ORTERONEL; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; SERINE; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR ETS; UNCLASSIFIED DRUG;

CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); CROSS RESISTANCE; DRUG EFFICACY; DRUG TARGETING; FUSION GENE; HUMAN; NOTE; ONCOGENE; OVERALL SURVIVAL; TREATMENT FAILURE;

EID: 84907709999     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00295     Document Type: Note

References (30)

1. Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Fedor, H. L., Lotan, T. L., Zheng, Q., De Marzo, A. M., Isaacs, J. T., Isaacs, W. B., Nadal, R., Paller, C. J., Denmeade, S. R., Carducci, M. A., Eisenberger, M. A., and Luo, J. (2014). AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. N Engl J Med
2. Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., Escara-Wilke, J., Wilder-Romans, K., Dhanireddy, S., Engelke, C., Iyer, M. K., Jing, X., Wu, Y. M., Cao, X., Qin, Z. S., Wang, S., Feng, F. Y., and Chinnaiyan, A. M (2014). Therapeutic targeting of BET bromodomain proteins in castrationresistant prostate cancer. Nature. 510, 278-82
3. Attard, G., Reid, A. H., Olmos, D., and de Bono, J. S. (2009a). Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 69, 4937-40
4. Attard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., Oommen, N. B., Hawche, G., Jameson, C., Thompson, E., Sipkema, R., Carden, C. P., Parker, C., Dearnaley, D., Kaye, S. B., Cooper, C. S., Molina, A., Cox, M. E., Terstappen, L. W., and de Bono, J. S. (2009b). Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res. 69, 2912-8
5. Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., Davis, I. D., de Bono, J. S., Evans, C. P., Fizazi, K., Joshua, A. M., Kim, C. S., Kimura, G., Mainwaring, P., Mansbach, H., Miller, K., Noonberg, S. B., Perabo, F., Phung, D., Saad, F., Scher, H. I., Taplin, M. E., Venner, P. M., and Tombal, B. (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371, 424-33
6. Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A Y., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C., Onofrio, R., Carter, S. L., Park, K., Habegger, L., Ambrogio, L., Fennell, T., Parkin, M., Saksena, G., Voet, D., Ramos, A. H., Pugh, T. J., Wilkinson, J., Fisher, S., Winckler, W., Mahan, S., Ardlie, K., Baldwin, J., Simons, J. W., Kitabayashi, N., MacDonald, T. Y., Kantoff, P. W., Chin, L., Gabriel, S. B., Gerstein, M. B., Golub, T. R., Meyerson, M., Tewari, A., Lander, E. S., Getz, G., Rubin, M. A., and Garraway, L. A. (2011) The genomic complexity of primary human prostate cancer. Nature. 470, 214-20
7. Bruno, R. D., Vasaitis, T. S., Gediya, L. K., Purushottamachar, P., Godbole, A. M., Ates-Alagoz, Z., Brodie, A. M., and Njar, V. C. (2011). Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids. 76, 1268-79
8. Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., Scardino, P. T., Rosen, N., and Sawyers, C. L. (2011). Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 19, 575-86
9. Carver, B. S., Tran, J., Chen, Z., Carracedo-Perez, A., Alimonti, A., Nardella, C., Gopalan, A., Scardino, P. T., Cordon-Cardo, C., Gerald, W., and Pandolfi, P. P (2009a). ETS rearrangements and prostate cancer initiation. Nature. 457, E1; discussion E2-3
10. Carver, B. S., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A., Alimonti, A., Nardella, C., Varmeh, S., Scardino, P. T., Cordon-Cardo, C., Gerald, W., and Pandolfi, P. P. (2009b). Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 41, 619-24
11. Chang, K. H., Li, R., Kuri, B., Lotan, Y., Roehrborn, C. G., Liu, J., Vessella, R., Nelson, P. S., Kapur, P., Guo, X., Mirzaei, H., Auchus, R. J., and Sharifi, N. (2013). A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell. 154, 1074-84
12. Claessens, F., Denayer, S., Van Tilborgh, N., Kerkhofs, S., Helsen, C., and Haelens, A (2008). Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl Recept Signal. 6, e008
13. de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Jr., Saad, F., Staffurth, J. N., Mainwaring, P., Harland, S., Flaig, T. W., Hutson, T. E., Cheng, T., Patterson, H., Hainsworth, J D., Ryan, C. J., Sternberg, C. N., Ellard, S. L., Flechon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C M., and Scher, H. I. (2011). Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 364, 1995-2005
14. Garraway, L. A., and Sellers, W. R. (2006). Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer. 6, 593-602
15. Hendriksen, P. J., Dits, N. F., Kokame, K., Veldhoven, A., van Weerden, W. M., Bangma, C. H., Trapman, J., and Jenster, G. (2006). Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res. 66, 5012-20
16. Lorente, D., and De Bono, J. S. (2014). Molecular alterations and emerging targets in castration resistant prostate cancer. Eur J Cancer. 50, 753-64
17. Mezynski, J., Pezaro, C., Bianchini, D., Zivi, A., Sandhu, S., Thompson, E., Hunt, J., Sheridan, E., Baikady, B., Sarvadikar, A., Maier, G., Reid, A. H., Mulick Cassidy, A., Olmos, D., Attard, G., and de Bono, J. (2012). Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 23, 2943-7
18. Montgomery, B., Kheoh, T., Molina, A., Li, J., Bellmunt, J., Tran, N., Loriot, Y., Efstathiou, E., Ryan, C. J., Scher, H. I., and de Bono, J. S. (2014). Impact of Baseline Corticosteroids on Survival and Steroid Androgens in Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis from COU-AA-301 Eur Urol
19. Mostaghel, E. A., Plymate, S. R., and Montgomery, B. (2014). Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit. Clin Cancer Res. 20, 791-8
20. Noonan, K. L., North, S., Bitting, R. L., Armstrong, A. J., Ellard, S. L., and Chi, K. N (2013). Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 24, 1802-7
21. Petrovics, G., Liu, A., Shaheduzzaman, S., Furusato, B., Sun, C., Chen, Y., Nau, M., Ravindranath, L., Dobi, A., Srikantan, V., Sesterhenn, I. A., McLeod, D. G., Vahey, M., Moul, J. W., and Srivastava, S. (2005). Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 24, 3847-52
22. Petrylak, D. P., Tangen, C. M., Hussain, M. H., Lara, P. N., Jr., Jones, J. A., Taplin, M E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., Benson, M. C., Small, E. J., Raghavan, D., and Crawford, E. D. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351, 1513-20
23. Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., Carles, J., Mulders, P. F., Basch, E., Small, E. J., Saad, F., Schrijvers, D., Van Poppel, H., Mukherjee, S D., Suttmann, H., Gerritsen, W. R., Flaig, T. W., George, D. J., Yu, E. Y., Efstathiou, E., Pantuck, A., Winquist, E., Higano, C. S., Taplin, M. E., Park, Y., Kheoh, T., Griffin, T., Scher, H. I., and Rathkopf, D. E. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 368, 138-48
24. Scher, H. I., Buchanan, G., Gerald, W., Butler, L. M., and Tilley, W. D. (2004). Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 11, 459-76
25. Scher, H. I., Fizazi, K., Saad, F., Taplin, M. E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., Armstrong, A. J., Flaig, T. W., Flechon, A., Mainwaring, P., Fleming, M., Hainsworth, J. D., Hirmand, M., Selby, B., Seely, L., and de Bono, J. S. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 367, 1187-97
26. Schrader, A. J., Boegemann, M., Ohlmann, C. H., Schnoeller, T. J., Krabbe, L. M., Hajili, T., Jentzmik, F., Stoeckle, M., Schrader, M., Herrmann, E., and Cronauer, M. V. (2014). Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol. 65, 30-6
27. Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Theodore, C., James, N. D., Turesson, I., Rosenthal, M. A., and Eisenberger, M A. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351, 1502-12
28. Thomsen, F. B., Roder, M. A., Rathenborg, P., Brasso, K., Borre, M., and Iversen, P (2014). Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scand J Urol. 48, 268-75
29. van Soest, R. J., van Royen, M. E., de Morree, E. S., Moll, J. M., Teubel, W., Wiemer, E. A., Mathijssen, R. H., de Wit, R., and van Weerden, W. M. (2013). Crossresistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castrationresistant prostate cancer. Eur J Cancer. 49, 3821-30
30. Yuan, X., Cai, C., Chen, S., Yu, Z., and Balk, S. P. (2014). Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene. 33, 2815-25